Örn Almarsson

Leading Axelyf ehf's charge in pharmaceutical and biotechnology innovation, my focus lies in development of therapies for human health. Our team's commitment to delivering new therapies in immunotherapies started with the passion to transform the natural lipid Astaxanthin from a nutritional to a pharmaceutical to treat patients needing an easy-to-use, safe oral medication. Axelyf is developing RNA medicines in autoimmune disease and oncology with a distinctive profiles that include significantly improved lipid nanoparticles (LNPs) for delivery - potent and selective yet lacking immune stimulation which is a common feature of LNPs. Axelyf values of excellence, transparency and integrity are guiding our vision towards impactful healthcare solutions.Previously, as head of delivery science and process chemistry at Moderna I helped to advance the LNPs that are now in Moderna´s products and pipeline. The book end to my experience is the foundational start I was privileged to get at Merck in the mid 1990s. With 3 decades in industry behind me, I am keen to continue to leverage my strong foundation in pharmaceutical science and a deep understanding of the biotech/pharma landscape to make a positive impact on human health.